110 related articles for article (PubMed ID: 23040618)
1. Guest editorial: Bilateral orchidectomy should not be considered an obsolete alternative for metastatic cancer of the prostate.
Morales A
Can J Urol; 2012 Oct; 19(5):6414-6. PubMed ID: 23040618
[No Abstract] [Full Text] [Related]
2. Testosterone measurement in patients with prostate cancer.
Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
[TBL] [Abstract][Full Text] [Related]
3. [GnRH antagonists--a new therapy option for advanced prostate cancer].
Wolff JM
Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
[TBL] [Abstract][Full Text] [Related]
4. Is hormone ablation still the right choice for advanced prostate cancer?
Fitzpatrick JM
BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
[No Abstract] [Full Text] [Related]
5. Hormonal consequences of orchidectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels.
Boccon-Gibod L; Laudat MH; Guiban D; Steg A
Eur Urol; 1988; 15(1-2):99-102. PubMed ID: 3215246
[TBL] [Abstract][Full Text] [Related]
6. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
7. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.
Anvari K; Seilanian Toussi M; Kalantari M; Naseri S; Karimi Shahri M; Ahmadnia H; Katebi M; Sedighi Pashaki A; Dayani M; Broumand M
Urol J; 2012; 9(1):381-8. PubMed ID: 22395836
[TBL] [Abstract][Full Text] [Related]
8. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
9. [Hormone therapy in advanced and generalized carcinoma of the prostate].
Vachalovský V; Dvorácek J; Voboril V
Cas Lek Cesk; 1998 Aug; 137(17):532-6. PubMed ID: 9787507
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
[No Abstract] [Full Text] [Related]
11. Physiologic basis of endocrine therapy for prostatic cancer.
McConnell JD
Urol Clin North Am; 1991 Feb; 18(1):1-13. PubMed ID: 1899494
[TBL] [Abstract][Full Text] [Related]
12. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K
Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408
[No Abstract] [Full Text] [Related]
13. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
[TBL] [Abstract][Full Text] [Related]
14. [Hormone therapy in prostate cancer: clinical results].
Morote-Robles J
Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
[TBL] [Abstract][Full Text] [Related]
15. Advanced prostate cancer: what's new in hormonal manipulation?
Brewster SF; Gillatt DA
Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
[TBL] [Abstract][Full Text] [Related]
16. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
17. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
18. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
19. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Smith MR
Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
[TBL] [Abstract][Full Text] [Related]
20. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
[Next] [New Search]
